checkAd

Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005725/en/

SWIFF-CAR Mechanism (Photo: Business Wire)

SWIFF-CAR Mechanism (Photo: Business Wire)

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the publication of a study in BMC Biotechnology, a Springer Nature journal, describing and evaluating the development of the SWIFF-CAR, a CAR construct with an embedded on/off-switch, which enables tight control of the CAR surface presentation and subsequent cytolytic functions using a small molecule drug. The reversible control of these engineered T-cells represents a promising approach to further mitigate the potential toxicities that are associated with CAR T-cell administration in clinical settings and to improve the process of CAR T-cell production for specific target antigens.

“Following Cellectis’ previously developed CubiCAR system, an all-in-one CAR architecture with an embedded multi-functional tag for purification, detection and elimination of CAR T-cells, we knew that we needed an additional ‘on/off switch’ to direct T-cells to either be active or inert, without necessarily killing them,” said Dr. Alexandre Juillerat, Ph.D., Project Leader and U.S. Laboratory Head, Cellectis. “The SWIFF-CAR system does precisely that, representing a major breakthrough in our ongoing efforts to develop innovative applications to treat a range of diseases, including cancer and autoimmune diseases.”

“While suicide gene systems have proven to be an effective way to eliminate transduced CAR T-cells, they also potentially terminate CAR T-cell treatment altogether,” added Dr. Philippe Duchateau, Ph.D., Chief Scientific Officer, Cellectis. “The capability to manipulate CAR surface presentation improves the safety of CAR-T therapies and enhances our ability to circumvent hurdles associated with manufacturing. The SWIFF-CAR system addresses both of these factors and is an important next step for Cellectis in treating deadly illnesses that affect patients globally.”

Seite 1 von 2
Cellectis Share Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
08.07.2019, 22:30  |  382   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005725/en/SWIFF-CAR Mechanism (Photo: Business Wire) Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - …

Nachrichten des Autors

Titel
Titel
Titel
Titel